Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Antheia has joined forces with Ginkgo Bioworks to strengthen its efforts in developing and producing essential medicines to treat a wide range of diseases.
Artiva Biotherapeutics is quadrupling its footprint in San Diego with a 52,000 square-foot corporate HQ, R&D and manufacturing center opening next year.
The U.S. FDA greenlit the combination of Keytruda and Eisai’s Lemvima as a first-line treatment for adult patients with advanced renal cell carcinoma.
Citing a study from Johns Hopkins University, researchers found that immunocompromised people are 485 times more likely to end up in the hospital or die from COVID-19.
Trying to get clinical trials enrolled and completed creates a bottleneck that has hindered drug development for years. With a fresh $220 million in hand, Reify Health is looking to change that.
I-Mab announced positive interim data from its U.S. Phase II/III clinical trial of plonmarlimab for treatment of cytokine release syndrome in severe COVID-19.
Emergent BioSolutions has approval to resume manufacturing vaccines, but its lawsuit issues haven’t gone away as easily.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Women who are pregnant are more vulnerable to developing severe illness after infection with SARS-Cov-2, the novel coronavirus that causes COVID-19.
BioSpace recently spoke with James Oliviero, CEO and president at Checkpoint Therapeutics, an immuno-oncology, late-stage development company.
The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.
The FDA indicated the drug couldn’t be approved in its present form and asked for another clinical trial of the drug be run before they reapplied.